Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Capital Expenditures (2016 - 2025)

Agios Pharmaceuticals' Capital Expenditures history spans 14 years, with the latest figure at $4.0 million for Q4 2025.

  • For Q4 2025, Capital Expenditures rose 145.07% year-over-year to $4.0 million; the TTM value through Dec 2025 reached $4.3 million, up 156.14%, while the annual FY2025 figure was $4.3 million, 156.14% up from the prior year.
  • Capital Expenditures reached $4.0 million in Q4 2025 per AGIO's latest filing, up from $214000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $4.8 million in Q3 2022 to a low of -$2.8 million in Q2 2022.
  • Average Capital Expenditures over 5 years is $663947.4, with a median of $299000.0 recorded in 2024.
  • The largest YoY upside for Capital Expenditures was 713.81% in 2022 against a maximum downside of 1221.69% in 2022.
  • A 5-year view of Capital Expenditures shows it stood at $1.2 million in 2021, then tumbled by 90.52% to $113000.0 in 2022, then plummeted by 728.32% to -$710000.0 in 2023, then surged by 328.73% to $1.6 million in 2024, then skyrocketed by 145.07% to $4.0 million in 2025.
  • Per Business Quant, the three most recent readings for AGIO's Capital Expenditures are $4.0 million (Q4 2025), $214000.0 (Q3 2025), and -$644000.0 (Q2 2025).